Vertex shareholders approve 2026 Stock Plan, all director nominees, and shareholder written consent proposal

VERTEX PHARMACEUTICALS INC / MA

All 10 director nominees elected; CEO Reshma Kewalramani received ~221.9M votes.
Shareholders ratified Ernst & Young as independent auditor for 2026 (223.5M for).
Advisory say-on-pay passed with 207.9M votes for vs. 14.5M against.
2026 Stock and Option Plan approved (216.1M for, 6.5M against), replacing 2013 plan.
Shareholder proposal for right to act by written consent passed (126.9M for vs. 95.8M against).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.